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Abstract
Background: Two criteria based on a 2 h 75 g OGTT are being used for the diagnosis of gestational diabetes
(GDM), those recommended over the years by the World Health Organization (WHO), and those recently
recommended by the International Association for Diabetes in Pregnancy Study Group (IADPSG), the latter
generated in the HAPO study and based on pregnancy outcomes. Our aim is to systematically review the evidence
for the associations between GDM (according to these criteria) and adverse outcomes.
Methods: We searched relevant studies in MEDLINE, EMBASE, LILACS, the Cochrane Library, CINHAL, WHO-Afro
library, IMSEAR, EMCAT, IMEMR and WPRIM. We included cohort studies permitting the evaluation of GDM
diagnosed by WHO and or IADPSG criteria against adverse maternal and perinatal outcomes in untreated women.
Only studies with universal application of a 75 g OGTT were included. Relative risks (RRs) and their 95% confidence
intervals (CI) were obtained for each study. We combined study results using a random-effects model.
Inconsistency across studies was defined by an inconsistency index (I
2) > 50%.
Results: Data were extracted from eight studies, totaling 44,829 women. Greater risk of adverse outcomes was
observed for both diagnostic criteria. When using the WHO criteria, consistent associations were seen for
macrosomia (RR = 1.81; 95%CI 1.47-2.22; p < 0.001); large for gestational age (RR = 1.53; 95%CI 1.39-1.69; p <
0.001); perinatal mortality (RR = 1.55; 95% CI 0.88-2.73; p = 0.13); preeclampsia (RR = 1.69; 95%CI 1.31-2.18; p <
0.001); and cesarean delivery (RR = 1.37;95%CI 1.24-1.51; p < 0.001). Less data were available for the IADPSG criteria,
and associations were inconsistent across studies (I
2 ≥ 73%). Magnitudes of RRs and their 95%CIs were 1.73 (1.28-
2.35; p = 0.001) for large for gestational age; 1.71 (1.38-2.13; p < 0.001) for preeclampsia; and 1.23 (1.01-1.51; p =
0.04) for cesarean delivery. Excluding either the HAPO or the EBDG studies minimally altered these associations, but
the RRs seen for the IADPSG criteria were reduced after excluding HAPO.
Conclusions: The WHO and the IADPSG criteria for GDM identified women at a small increased risk for adverse
pregnancy outcomes. Associations were of similar magnitude for both criteria. However, high inconsistency was
seen for those with the IADPSG criteria. Full evaluation of the latter in settings other than HAPO requires additional
studies.
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The definition of gestational diabetes mellitus (GDM) as
a n yd e g r e eo fg l u c o s ei n t o l e r a n c ew i t ho n s e to rf i r s t
recognition during pregnancy is largely accepted. How-
ever, the precise level of glucose intolerance characteriz-
ing gestational diabetes has been controversial over the
last three decades.
In 1979-1980, U.S. National Diabetes Data Group
( N D D G )[ 1 ]a n dt h eW o r l dH e a l t hO r g a n i z a t i o n
(WHO) [2] established that the 2 h 75 g oral glucose
tolerance test (OGTT) should be the main diagnostic
test for glucose intolerance outside of pregnancy.
Regarding glucose intolerance during pregnancy, two
different approaches were taken. The NDDG opted, in
pregnancy, to maintain the 3 h 100 g OGTT test, largely
used and evaluated in the USA. The American Diabetes
Association (ADA) and many other medical associations
around the world adopted over the years this 3 h 100 g
OGTT test. In so doing, different cutoffs for the diagno-
sis of GDM were chosen, one of the issues being the diffi-
culty in converting blood glucose values from the original
studies done in the 1960s and 1970s [1,3-5] to their
plasma equivalents analyzed using new analytic methods.
The WHO adopted the 2 h 75 g OGTT in pregnancy,
recommending the same diagnostic cut points estab-
lished for the diagnosis of impaired glucose tolerance
outside of pregnancy [2,3]. In 1999, WHO clarified that
GDM encompassed impaired glucose tolerance and dia-
betes (fasting ≥ 7 mmol/l or ≥ 126 mg/dl; 2 h plasma
glucose ≥ 7.8 mmol/l or 140 mg/dl) [6] and, over the
years has maintained their recommendations.
More recently, the International Association of the
Diabetes in Pregnancy Study Group (IADPSG), after
extensive analyses of the Hyperglycemia and Adverse
Pregnancy Outcomes (HAPO) study [7], recommended
new diagnostic criteria for GDM [8] based on the 2 h
75 g OGTT: a fasting glucose ≥ 5.1 mmol/L (92 mg/dl),
or a one hour result of ≥ 10.0 mmol/L (180 mg/dl), or a
two hour result of ≥ 8.5 mmol/L (153 mg/dl).
A considerable number of prospective studies have now
investigated the use of a 2 h 75 g OGTT in pregnancy in
relation with various pregnancy outcomes, thus allowing
evaluation of these two main diagnostic criteria. Thus, the
purpose of this study is to summarize, through a systematic
review, the association of GDM, as diagnosed by the WHO
and the IADPSG criteria, with adverse pregnancy outcomes,
in untreated women. In so doing, the applicability of the
IADPSG criteria to non-HAPO settings is also evaluated.
Methods
Criteria for considering studies for this review
Types of study
Cohort studies (prospective or retrospective) were con-
sidered for inclusion in this systematic review if they
provided sufficient information to estimate the associa-
tions of the WHO and/or the IADPSG criteria with
related perinatal and maternal outcomes.
To avoid selection bias, we included only studies that
applied the OGTT universally to all participants. We there-
fore excluded studies applying the OGTT only in women
with certain clinical risk factors (such as family history,
obesity, previous GDM) or in those positive in pre-OGTT
glucose screening (with, for example, a 50 g challenge test
and/or a fasting glucose). We also excluded studies that
did not distinguish pre-gestational diabetes mellitus from
GDM, those not allowing the distinction between treated
and untreated groups, and those not reporting outcomes
for women classified as having a normal OGTT.
Types of participants
We accepted studies which included women of any race,
parity, age, body weight or other socio-demographic
characteristics.
Types of diagnostic tests
Only studies based on a 2 hour 75 g OGTT performed
during the 2
nd or the 3
rd trimesters were included, and
only if they provided results for a diagnosis based on at
least the 2 h post-load glucose. Studies based on capillary
glucose measurements were included.
Types of outcome measures
We decided to analyze, as perinatal outcomes, large for
gestational age births and macrosomia (as defined by the
authors), as well as perinatal mortality (fetal death and
early neonatal death). Regarding maternal outcomes, we
chose to analyze cesarean delivery and preeclampsia
according to individual study definitions.
Search methods for the identification of studies
The search strategy used the following general terms,
adapted to each database: “gestational diabetes” or “gluco-
seintolerance” and the appropriate terms for each of the
maternal and perinatal adverse outcomes specified above.
Specific terms used for the electronic search are detailed
in the Additional file 1: Description of the electronic
search strategy used to perform the literature search.
We searched ten electronic databases (MEDLINE,
EMBASE, LILACS, the Cochrane Library (CENTRAL),
CINHAL, WHO-Afro library, IMSEAR, EMCAT, IMEMR
and WPRIM) for articles published from inception up to
March 15, 2011. No language or country restrictions were
applied. We also searched for additional studies from clas-
sical review articles. The reference lists of all articles
selected for full text reading were reviewed for additional
potentially eligible studies.
Data collection and analysis
Selection of studies
All citations identified were entered into an electronic
database and duplicates were deleted. Initially, two
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abstracts of potentially relevant studies for eligibility.
When the information was not sufficient to determine if
the article was eligible for inclusion, the article’s full text
was obtained for further evaluation. Discrepancies were
discussed until consensus was reached.
Data extraction and management
Two independent investigators reviewed the eligible stu-
dies and extracted data using a standardized form pre-
pared for this review. Disagreements were discussed and
resolved in a consensus meeting. When raw quantitative
data were not reported, approximate values were obtained
from the figures or calculated from percentages.
Assessment of methodological quality
The methodological quality of the included studies was
assessed by examining factors which might affect the
strength of the association between glucose levels and out-
comes. In particular, the following factors were assessed in
each study: i) adequate selection of participants: consecu-
tive recruitment from prenatal clinics; ii) adequate stan-
dardization of the glucose tolerance test (pre-analytic
factors such as anhydrous glucose, plasma immediately
separated or kept with glycolytic inhibitors and kept refri-
gerated until centrifugation; and analytic factors such as
enzymatic method of measurement and laboratory quality
control); iii) adequate report of losses to follow up and; iv)
medical staff blinded to OGTT results.
Data synthesis
Data for the WHO and the IADPSG criteria were aggre-
gated and presented as relative risk (RR) with 95% confi-
dence interval (CI). Meta-analysis data were combined
using random-effect models, with restricted maximum-
likelihood (REML) estimation. The statistical analysis was
performed using the R version 2.11.1 software, package
metafor version 1.6-0 [9]. As our aim was to investigate
diagnostic criteria based on their capacity to predict
GDM-related outcomes for classification purposes rather
than for etiological investigation, all statistical analyses
were crude, without adjustment for potential confounders.
Assessment of heterogeneity
Overall results were calculated based on the random
effects model. We assessed heterogeneity using the
Cochrane’s c2 statistics with a significance level of 0.10.
Inconsistency indexes (I
2) were also calculated, and a value
greater than 50% was considered an indicator of high
inconsistency between studies [10].
Sensitivity analysis and assessment of publication bias
We did sensitivity analyses in order to examine the
influence of the HAPO study and Brazilian Study of
Gestational Diabetes (EBDG) on the magnitude and
consistency of associations with outcomes. In addition
to REML, we also aggregated data with other variance
estimators (Maximum Likelihood, Empirical Bayes,
Sidik-Jonkman and DerSimonean and Laird) and with a
fixed effect model in order to assess the robustness of
the model.
Publication bias was tested using a funnel plot and
Egger’s test based on weighted regression [11].
T h ef u l ld a t a b a s ef o rt h eE B D Gs t u d yw a sa v a i l a b l e
which allowed analysis for both criteria for all outcomes.
The EBDG study was approved by local institutional
review boards and informed consent was obtained from
all participants. Data from the other studies were
obtained from published articles cited in the list of
references.
Results
Results of the literature search
Figure 1 (flow chart) describes the process of study iden-
tification and inclusion, and the reasons for exclusions.
Our search identified 5985 references, without duplicates.
Nine citations were retrieved from the reference lists of
the full-text articles. After revising all titles and abstracts,
202 potentially relevant citations were identified and full
papers were obtained for all. A total of 9 publications
pertaining to 8 studies met the selection criteria and
were included in this systematic review. For a description
of excluded studies, see Additional file 2: List of excluded
articles. The full database for the EBDG study was avail-
able which allowed analysis for both criteria for all
outcomes.
Included studies
Data on the adverse outcomes associated with diagnostic
criteria were extracted from 8 studies (9 publications)
[7,12-19], all of which were published in full in peer
reviewed journals (Table 1). Of the 8 included studies,
three were retrospective and information was gathered
through data linkage or chart review [15,17,18]. One
study was performed in the United States [13], one in
Asia [18], two in the Middle East [17], one in Europe
[12], two in Latin America [14,16] and one was a multi
country study [7,19]. All but one study [12] used venous
plasma glucose based on the oral glucose tolerance test
to diagnose GDM. Taken together, the 8 studies pro-
vided information on a total of 44829 women. The data-
base of the Brazilian Study of Gestational Diabetes
(EBDG) [16] was used to generate data when results
from other studies were not available from the pub-
lished literature.
We only analyzed results for untreated women.
Because of the ethical need to offer treatment to women
identified as having GDM by the diagnostic criteria in
use at the moment of the testing, some studies excluded
such women and others presented results permitting the
separation of those who received treatment. As seen in
Table 1 in some cases, this resulted in study samples
with a very narrow glucose range.
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ized in Table 2. Most of the studies (6/8) had adequate
selection of participants, half of them presented ade-
quate test standardization and reported losses to follow-
up and only one study informed that medical staff was
blinded to OGTT results.
Perinatal outcomes
As seen in Figure 2, a total of five studies allowed eva-
luation of the association between GDM diagnosed
through WHO criteria and fetal macrosomia (defined by
authors as birth weight > 4000 g, except Aberg et al
[12]). The corresponding pooled relative risk (RR) was
1.81 (95%CI 1.47-2.22; p < 0.001), with very homoge-
n o u sr e s u l t sa c r o s ss t u d i e s( I
2 =0 % ) .W ed i dn o ti d e n -
tify any published study allowing evaluation of
macrosomia according to the IADSPG diagnostic cri-
teria. Therefore, we performed this analysis using the
EBDG database and the RR was 1.38 (95%CI 1.14-1.68;
p = 0.001).
ZĞĐŽƌĚƐŝĚĞŶƚŝĨŝĞĚƚŚƌŽƵŐŚĚĂƚĂďĂƐĞ
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Figure 1 Flow chart for the process of study identification and inclusion.
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Page 4 of 13When we assessed large for gestational age births, defined
as birthweight ≥ 90
th percentile for gestational age (Figure
3), the association seen for the WHO criteria (four studies)
was slightly lower (RR = 1.53, 95% CI 1.39-1.69; p < 0.001),
and very homogeneous across studies (I
2 =0 % ) .R e g a r d i n g
the IADPSG criteria, the large inconsistency across the
three studies evaluated (I
2 = 93%) limited the validity of the
pooled RR (1.73; 95%CI 1.28-2.35; p = 0.001).
With regard to perinatal mortality (Figure 4), only two
studies provided sufficient data for the evaluation of the
WHO criteria. Their summary produced a homogenous
(I
2 = 0%) association of clinically relevant size but lack-
ing statistical significance (RR = 1.55, 95%CI 0.88-2.73;
p = 0.128). No studies were available to evaluate the
IADSPG diagnostic criteria with regard to perinatal
mortality. Analysis with the EBDG database yielded
Table 1 Main characteristics of the studies included
Study N Incidence
of GDM
(%)
1
Ethnicity Maternal
age
2
Gestational
age at
OGGT
(weeks)
2
Pre-gravid BMI
2 Study criteria for
GDM treatment
3
mmol/L
Aberg 2001
[12] Sweden
4773 5.2 Not reported Not
reported
25-30 Not reported 2 hs PG > 9.0
Black 2010
[13] USA
8711 19.4 White: 7.2; Black:
10.;1 Hispanic: 74.4;
Asian: 7.4; Other: 0.9
29.1 ± 5.9 26.7 ± 2.9 27.5 ± 6.1 At least 2 abnormal
values: FPG ≥ 5.5; 1
hPG ≥ 10.8; 2 hPG ≥
8.9
EBDG 2001
[16] Brazil
4998 7.5 White: 44.9 Mixed:
41.1 Black: 13.6
Other: 0.4
27.8 ± 5.5 24-28 23.4 ± 4.0 2 hPG ≥ 10.0
Forsbach
1997 [14]
Mexico
667 16.0 Hispanic 18 - 44 34.2 (24-40) Not reported 2 hPG > 10.0
HAPO 2008,
2010 [7,19]
multi-
countries
23316 11.4 White: 48.3 Black:
11.6 Hispanic: 8.5
Asian: 29.0 Other:
2.6
29.2 ± 5.8 27.8 ± 1.8 27.7 ±
5.1
FPG > 5.8; or 2 hPG > 10.0;
or RPG ≥ 8.9
Khan 1994
[15] Pakistan
1278 4.9 Not reported 26.7 ± 4.6 16 - 20 Not
reported
. At least 2 abnormal values:
FPG > 5.8; 1 hPG > 10.3; 2
hPG > 7.8/3 hPG > 6.8
Shirazian
2008 [17] Iran
670 12.1 Not reported NR 24-28 Not
reported
At least 2 abnormal values:
FPG ≥ 5.5; 1 hPG ≥ 10.0; 2
hPG ≥ 8.3
Sugaya 2000
[18] Japan
416 32.5 Asian 30.3 ± 4.3 25.4 ± 8.2 22.4 ±
3.8
At least 2 abnormal values:
FPG ≥ 5.5; 1 hPG ≥ 10.0; 2
hPG ≥ 8.3
GDM: Gestational diabetes; OGTT: Oral glucose tolerance test; PG: Plasma glucose; FPG: Fasting PG; RPG: random PG
1 GDM incidence according to WHO except for Black et al., who used the IASDPG criteria
2 Range or mean ± SD
3 The meta-analyses only included untreated women, as defined in each study
Table 2 Assessment of methodological quality of included studies
Study Adequate selection of
participants
Adequate test
standardization
Adequate report of losses to
follow-up
Medical staff blinded to OGTT
results
Aberg, 2001 [1] Uncertain No Uncertain No
Black, 2010 [13] Yes Uncertain Yes No
EBDG, 2001 [16] Yes Yes Yes No
Forsbach, 1997
[14]
Yes Yes Uncertain No
HAPO, 2008, 2010
[7,19]
Yes Yes Yes Yes
Khan, 1994 [15] Yes Uncertain Uncertain Uncertain
Shirazian, 2008 [17] Yes Yes No Uncertain
Sugaya, 2000 [18] Uncertain Uncertain Yes No
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Overall effect: p=0.001
Aberg 2001
EBDG 2001
Forsbach 1997
Kahn 1994
Shirazaian 2008
Events
87
13
57
 9
 6
 2
Total
664
131
328
 87
 63
 55
GDM
Events
717
204
425
 29
 40
 19
Total
10924
 4526
 4049
  560
 1215
  574
Non-GDM
RR
1.81
2.20
1.66
2.00
2.89
1.10
95%−CI
 [1.47; 2.22]
 [1.29; 3.75]
 [1.29; 2.13]
 [0.98; 4.08]
 [1.27; 6.57]
 [0.26; 4.59]
Weight
100%
15.2%
67.8%
 8.5%
 6.4%
 2.1%
WHO-criteria
EBDG 2001 114 802 368 3575
0.2 0.5 1 2 5
Relative Risk
1.38
    
 [1.14; 1.68] 100%
IADPSG-criteria
Heterogeneity: Q=2.8, p=0.593;  I2=0%
Overall effect: p<0.001
Figure 2 Relative incidence (RR) of macrosomia among those with and without gestational diabetes as defined by WHO and IADPSG
diagnostic criteria.
Events Total
GDM
Events Total
Non-GDM
RR 95%−CI Weight
WHO-criteria
0.2 0.5 1 2 5
Relative Risk
IADPSG-criteria
Heterogeneity: Q=15.8, p<0.001;  I2=93%
Overall effect: p=0.001
Heterogeneity: Q=0.4, p=0.933;  I2=0%
Overall effect: p<0.001
Total
EBDG 2001
HAPO 2008
Kahn 1994
Sugaya 2000
422
 45
361
 10
  6
3054
 294
2642
  63
  55
2333
 334
1860
 118
  21
25701
 3630
20575
 1215
  281
1.53
1.66
1.51
1.63
1.46
 [1.39; 1.69]
 [1.25; 2.22]
 [1.36; 1.68]
 [0.90; 2.96]
 [0.62; 3.45]
100%
11.3%
84.7%
 2.7%
 1.3%
Total
Black 2010
EBDG 2001
HAPO 2008
956
264
 87
605
6201
1691
 772
3738
2436
 528
 292
1616
29701
 7020
 3202
19479
1.73
2.08
1.24
1.95
 [1.28; 2.35]
 [1.81; 2.38]
 [0.99; 1.55]
 [1.79; 2.13]
100%
34%
30.5%
35.5%
Figure 3 Relative incidence (RR) of large for gestational age infants among those with and without gestational diabetes as defined by
WHO and IADPSG diagnostic criteria.
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Page 6 of 13similar, non-statistically significant, results (RR = 1.40,
95%CI 0.91-2.14; p = 0.122).
Maternal outcomes
Four studies [13,16,18,19] provided data on preeclampsia,
one of which included cases of transient hypertension or
unspecified hypertension in the same group as pree-
clampsia [13]. As presented in Figure 5, there was a posi-
tive and statistically significant association between the
WHO diagnostic criteria and preeclampsia (pooled RR =
1.69, 95%CI 1.31-2.18; p < 0.001) with reasonable consis-
tency across the three studies evaluated (I
2 = 38%). When
Overall effect: p=0.122
Events Total
GDM
Events Total
Non-GDM
RR 95%−CI Weight
WHO-criteria
IADPSG-criteria
Heterogeneity: Q=0.3, p=0.562;  I2=0%
Overall effect: p=0.128
Total
Aberg 2001
EBDG 2001
13
 1
12
456
126
330
114
 13
101
8616
4515
4101
1.55
2.76
1.48
 [0.88;  2.73]
 [0.36; 20.91]
 [0.82;  2.66]
100%
 7.8%
92.2%
EBDG 2001 27 812 86 3619 1.40
   
 [0.91; 2.14] 100%
0.1 0.5 1 2 10
Relative Risk
Figure 4 Association between perinatal mortality and gestational diabetes as defined by WHO and IADPSG diagnostic criteria.
Random effects model
Black 2010
EBDG 2001
HAPO 2010
524
184
 28
312
6026
1691
 895
3440
1385
 490
  91
 804
29026
 7020
 4082
17924
1.71
1.56
1.40
2.02
 [1.37; 2.14]
 [1.33; 1.83]
 [0.92; 2.13]
 [1.78; 2.29]
100%
39.4%
17.6%
    43%
Events Total
GDM
Events Total
Non-GDM
RR 95%−CI Weight
WHO-criteria
0.2 0.5 1 2 5
Relative Risk
IADPSG-criteria
Heterogeneity: Q=7.7, p<0.001;  I2=73%
Overall effect: p<0.001
Heterogeneity: Q=3.3, p=0.189;  I2=38%
Overall effect: p<0.001
Random effects model
EBDG 2001
HAPO 2010
Sugaya 2000
213
 19
179
 15
2759
 357
2347
  55
1088
 100
 937
  51
23918
 4620
19017
  281
1.69
2.46
1.55
1.50
 [1.31; 2.18]
 [1.52; 3.97]
 [1.33; 1.81]
 [0.91; 2.47]
100%
20.5%
60.2%
19.3%
Figure 5 Association between preeclampsia and gestational diabetes as defined by WHO and IADPSG diagnostic criteria.
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Page 7 of 13analyzed by the IADPSG criteria, the pooled RR for the
same outcome was of similar magnitude (RR = 1.71, 95%
CI 1.38-2.13; p < 0.001), but aggregated very inconsistent
results for the three available studies (I
2 = 73%).
Figure 6 presents data pertaining to studies with suffi-
cient information to evaluate diagnostic criteria as pre-
dictors for cesarean delivery. Both diagnostic criteria
detected women with an increased risk, the association
being slightly higher when GDM was diagnosed accord-
ing with the WHO criteria (RR = 1.37, 95%CI 1.24-1.51;
p < 0.001) than with the IADSPG criteria (RR = 1.23,
95%CI 1.01-1.51; p = 0.044). The associations were con-
sistent across the four studies analyzed according to the
WHO criteria (I
2 = 29%), but were inconsistent across
the three studies that used the IADSPG criteria (I
2 =
93%).
Sensitivity analyses and assessment of publication bias
Because the HAPO study was used to generate the
IADPSG criteria, we performed post hoc subgroup ana-
lysis excluding the HAPO study (Figure 7) for all out-
comes for which it contributed data. For the analyses of
the IADPSG criteria, the pooled RRs after exclusion
were always somewhat smaller than the RR for the
HAPO study alone. After exclusion, the pooled RRs
remained statistically significant for preeclampsia (p =
0.006), but not for large for gestational age and cesarean
delivery. For the analyses of the WHO criteria, the
pooled RRs excluding HAPO were generally greater
than the RR for the HAPO study alone, although not
statistically significantly so; and remained statistically
significant after the exclusion.
As the EBDG study was used in all analysis, some-
times using individual patient data from the original
database, we also performed post hoc sensitivity analyses
excluding this study (Figure 8). For the analyses of the
IADPSG criteria, this exclusion led to somewhat
increased pooled RRs, statistically different from the RRs
for the EBDG study for large for gestational age and
cesarean delivery; after the exclusion of the EBDG
study, the pooled RRs remained statistically significant.
For the analyses of the WHO criteria, pooled RRs were
generally smaller after exclusion of the EBDG study, but
remained statistically significant.
It was not possible to assess the influence of the
HAPO study on macrosomia, as no HAPO data were
available for this outcome. With respect to the influence
of the EBDG study, its exclusion led to an increase in
t h ep o o l e dR Rf o rt h eW H Oc r i t e r i a( f r o mR R1 . 8 1t o
RR 2.17).
Meta-analyses performed with different variance esti-
mators had little impact on the RR and on the I
2. Stron-
ger associations were found with fixed-effect models for
outcomes assessed with the IADPSG criteria (Additional
Events Total
GDM
Events Total
Non-GDM
RR 95%−CI Weight
WHO-criteria
0.2 0.5 1 2 5
Relative Risk
IADPSG-criteria
Heterogeneity: Q=34.1,  p<0.001;  I2=93%
Overall effect: p=0.044
Heterogeneity: Q=3.6,  p=0.302;  I2=29%
Overall effect: p<0.001
Total
Total
Aberg 2001
EBDG 2001
HAPO 2008
Sugaya 2000
742
 18
151
564
  9
2819
 129
 321
2314
  55
5058
 357
1498
3167
  36
27226
 4503
 4024
18418
  281
1.37
1.76
1.26
1.42
1.28
 [1.24; 1.51]
 [1.13; 2.73]
 [1.12; 1.43]
 [1.31; 1.53]
 [0.65; 2.50]
100%
 4,8%
37.2%
55.8%
 2.2%
Black 2010
EBDG 2001
HAPO 2008
1458
 336
 309
 813
5830
1691
 801
3338
5370
1112
1340
2918
27958
 7020
 3544
17394
1.23
1.25
1.02
1.45
 [1.01; 1.51]
 [1.12; 1.40]
 [0.93; 1.12]
 [1.36; 1.55]
100%
32.4%
33.1%
34.4%
Figure 6 Association between cesarean delivery and gestational diabetes as defined by WHO and IADPSG diagnostic criteria.
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Page 8 of 13file 3: Meta-analyses performed with different variance
estimators to generate pooled relative risks for the
IADSPG and WHO criteria for gestational diabetes in
the prediction of pregnancy outcomes).
Funnel plots and the Egger’s regression asymmetry
test (data not shown) did not reveal evidence for publi-
cation bias, although small number of studies compro-
mised this analysis.
LGA births
Total with the HAPO study
Subtotal without the 
HAPO study
Q=0.4, p=0.933; I2=0%
Subgroup difference: p=0.551
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Overall effect: p<0.001
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Overall effect: p=0.064
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 [1.81; 2.38]
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Cesarean  Delivery
Total with the HAPO study
Subtotal without the 
HAPO study
Q=3.6, p=0.302; I2=29%
Subgroup difference: p=0.677
Aberg 2001
EBDG 2001
Sugaya 2000
HAPO 2008
0.2 0.5 1 2 5
Relative Risk
RR 95%−CI
Overall effect: p<0.001
Q=2.02, p=0.364; I2=19%
Overall effect: p=0.003
Cesarean  Delivery
Total with the HAPO study
Subtotal without the 
HAPO study
Q=34.1, p<0.001; I2=93%
Subgroup difference: p=0.15
Black 2010
EBDG 2001
HAPO 2008
0.2 0.5 1 2 5
Relative Risk
RR 95%−CI
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Overall effect: p=0.239
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 [1.24; 1.51]
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 [1.12; 1.43]
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 [1.31; 1.53]
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1.13
    
1.25
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 [1.01; 1.51]
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 [1.12; 1.40]
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Preeclampsia
Total with the HAPO study  
Subtotal without the 
HAPO study
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Subgroup difference: p=0.532
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Figure 7 Sensitivity analysis excluding the HAPO study.
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This is the first systematic review to assess the magni-
tude of the associations between different GDM diag-
nostic criteria and several clinically relevant outcomes.
We focused analyses on the two main diagnostic criteria
currently under debate for a 75 g OGTT - i.e., those
recommended by the WHO and those recently pro-
p o s e db yt h eI A D S P Go nt h eb a s i so fp r e g n a n c y
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Subtotal without the 
EBDG study
Q=0.4, p=0.933; I2=0%
Subgroup difference: p=0.547
EBDG 2001
Kahn 1994
Sugaya 2000
HAPO 2008
0.2 0.5 1 2 5
Relative Risk
RR
1.53
1.51
    
1.66
1.63
1.46
1.51
95%−CI
 [1.39; 1.69 ]
 [1.36; 1.68]
 [1.25; 2.22]
 [0.90; 2.96]
 [0.62; 3.45]
 [1.36; 1.68]
Overall effect: p<0.001
Q=0.1, p=0.965; I2=0%
Overall effect: p<0.001
LGA Births
Total with the EBDG study
Subtotal without the 
EBDG study
Q=15.8, p<0.001; I2=93%
Subgroup difference: p<0.001
Black 2010
EBDG 2001
HAPO 2008
0.2 0.5 1 2 5
Relative Risk
RR 95%−CI
Overall effect: p=0.067
Q=0.6, p=0.456; I2=0%
Overall effect: p<0.001
1.73
1.99
    
2.08
1.24
1.95
 [1.28; 2.35]
 [1.85; 2.14]
 [1.81; 2.38]
 [0.99; 1.55]
 [1.79; 2.13]
Cesarean  Delivery
Total with the EBDG study
Subtotal without the 
EBDG study
Q=3.6, p=0.302; I2=29%
Subgroup difference: p=0.104
Aberg 2001
EBDG 2001
Sugaya 2000
HAPO 2008
0.2 0.5 1 2 5
Relative Risk
RR 95%−CI
Overall effect: p<0.001
Q=1, p=0.605; I2=0%
Overall effect: p<0.001
Cesarean  Delivery
Total with the EBDG study
Subtotal without the 
EBDG study
Q=34.1, p<0.001; I2=93%
Subgroup difference: p=0.025
Black 2010
EBDG 2001
HAPO 2008
0.2 0.5 1 2 5
Relative Risk
RR 95%−CI
Overall effect: p=0.685
Q=4.9, p=0.027; I2=80%
Overall effect: p<0.001
1.37
1.42
    
1.76
1.26
1.28
1.42
 [1.24; 1.51]
 [1.32; 1.54]
 [1.13; 2.73]
 [1.12; 1.43]
 [0.65; 2.50]
 [1.31; 1.53]
1.23
1.35
    
1.25
1.02
1.45
 [1.01; 1.51]
 [1.18; 1.57]
 [1.12; 1.40]
 [0.93; 1.12]
 [1.36; 1.55]
Preeclampsia
Total with the EBDG study  
Subtotal without the 
EBDG study
Q=3.3, p=0.189; I2=38%
Subgroup difference: p=0.069
EBDG 2001
Sugaya 2000
HAPO 2010
0.2 0.5 1 2 5
Relative Risk
RR 95%−CI
Overall effect: p<0.001
Q=0, p=0.911; I2=0%
Overall effect: p<0.001
1.69
1.54
    
2.46
1.50
1.55
 [1.31; 2.18]
 [1.33; 1.79]
 [1.52; 3.97]
 [0.91; 2.47]
 [1.33; 1.81]
Preeclampsia
Total with the EBDG study
Subtotal without the 
EBDG study
Q=7.7, p=0.021; I2=73%
Subgroup difference: p=0.425
Black 2010
EBDG 2001
HAPO 2010
0.2 0.5 1 2 5
Relative Risk
RR 95%−CI
Overall effect: p=0.112
Q=6.2, p=0.013; I2=84%
Overall effect: p<0.001
1.71
1.78
    
1.56
1.40
2.02
 [1.38; 2.13]
 [1.38; 2.30]
 [1.33; 1.83]
 [0.92; 2.13]
 [1.78; 2.29 ]
IADPSG CRITERIA WHO CRITERIA
Figure 8 Sensitivity analysis excluding the EBDG study.
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magnitude of the increased risk predicted by these two
criteria, we also evaluated the application of the
IADPSG criteria to settings other than that of the
HAPO study.
Our summary estimates of relative risk demonstrate
that GDM diagnostic criteria based on both the WHO
and the IADPSG criteria predict perinatal and maternal
adverse outcomes. The strength of the crude associa-
tions found ranged from 1.23 (95% CI 1.01-1.51) for
cesarean delivery, to 1.81 (95% CI 1.47-2.22) for macro-
somia. For the three outcomes for which meta-analyses
were possible for both criteria (large for gestational age,
preeclampsia and cesarean delivery), the magnitude of
the effects were similar for the WHO and the IADPSG
criteria (1.53 vs. 1.73; 1.69 vs. 1.71; 1.37 vs. 1.23, respec-
tively), although the inconsistency across studies limited
aggregate estimation for the IADPSG criteria. Sensitivity
analyses excluding either the HAPO or the EBDG study
did not materially change the magnitude of these asso-
ciations (changes varying between 1 and 13%).
It is important to note that these crude associations
a r ev e r ys m a l lw i t h i nad i a g n o s t i cc o n t e x t .T w or e a s o n s
may explain the small associations found. First, both
GDM criteria, especially the IADPSG criteria, identify
lesser degrees of hyperglycemia when compared to
other ones, such as those previously recommended by
the ADA [20]. Second, as all the studies analyzed in this
review excluded women receiving specific treatments for
GDM (see Table 1), the range of hyperglycemia classi-
fied as GDM represents a mild degree of hyperglycemia.
Given the continuum of risk in the association between
plasma glucose and pregnancy outcomes [7], if both cri-
teria were applied to a broader spectrum, such as the
one seen in the usual clinical setting, which includes
women at greater risk given their higher glucose level,
the association should be stronger. Nevertheless, even if
GDM diagnostic criteria were to reach relative risks
close to 3 for these adverse outcomes in such settings,
the relative risks would still be unlikely to reflect major
diagnostic discrimination in terms of post test probabil-
ities [21]. This fact suggests the importance of investi-
gating the contribution to risk discrimination of other
factors, besides glycaemia, for these outcomes.
It is also important to interpret the heterogeneity
found across studies, most seen for the IADPSG criteria.
Potential reasons for heterogeneity include different
population characteristics, study design and nature of
the diagnostic criteria. As sensitivity analyses examining
the influence of the EBDG and the HAPO studies did
reveal some changes in the heterogeneity found, particu-
larities about each of these study settings need to be
considered. The HAPO study is a large multi-country
study conducted from 2000 to 2006 with a strict
research protocol. The EBDG study is a multicenter
study conducted in Brazil in the 1990’sw i t hal e s ss t r i c t
protocol, in a scenario of less intervention, following
women with a wider range of hyperglycemia. A more
strict protocol, with more control over incomplete fast-
ing, such as that seen in the HAPO study, could pro-
duce larger associations with the IADPSG criteria,
which diagnoses an appreciable fraction of cases on the
basis of the fasting value. In fact, the application of the
IADPSG criteria in two published studies [13,22] and in
the EBDG database showed that the fasting value identi-
fied over 70% of all cases of GDM so defined, while
when these criteria were applied to the HAPO study as
a whole, the fasting value identified only about 50% of
cases. However, as this rate in HAPO varied from 24%
(Thailand) to 74% (Barbados)[23], whether these differ-
ences resulted from incomplete fasting or from other
specific study or population particularity cannot be con-
cluded from current information. The lack of blinding
to glucose levels in most studies (except HAPO) could
lead to GDM treatment, and thus reduce the magnitude
of the associations; so we excluded such women.
Although undetected intervention may still be present
even after these exclusions, for example, diet, it is unli-
kely that this would cause more heterogeneity in the
IADPSG than in the WHO analyses.
One hypothesis is that the IADPSG criteria are more
vulnerable to heterogeneity across different settings
because they allow that diagnosis be made on the basis
of only one out of three possible measures (fasting, 1 h
and 2 h). Given population variability in terms of the
probability of being positive by fasting and post load
values, as well as in terms of the possibility of having
incomplete fasting (drank coffee or tea with sugar; for
example), more heterogeneity could be found for the
IADPSG criteria. Another possibility, worth exploring in
future studies, is whether the heterogeneity stems from
differences in the prevalence or characteristics of obesity
in the underlying populations.
Additionally, since the IADPSG criteria were derived
from the HAPO study, lower performance of these cri-
teria in non-HAPO settings is to be expected. For large
for gestational age and for cesarean delivery, results
remained inconsistent across studies after excluding
HAPO, which makes questionable the estimates of
pooled RRs generated for these outcomes (the pooled
RRs found were lower and not statistically significant).
For preeclampsia, results across studies became consis-
tent, but with an RR (1.54; 95% CI 1.32-1.79) smaller (p
= 0.006) than that found for the HAPO study (2.02; 95%
CI 1.78-2.29).
Our study has some limitations. First, few studies were
available to evaluate important outcomes such as perina-
tal mortality and long-term outcomes in offspring. Yet,
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pregnancy related hypertension, two clinically relevant
outcomes. Second, as we excluded studies conducted
with selective screening and studies not allowing analy-
sis of untreated women, we eliminated several otherwise
good studies which were included in other reviews on
GDM screening [24]. Publication bias could not be
excluded because of the small number of studies
examined.
Our study also has several strong points, including its
originality, extensive search strategy, inclusion of studies
independent of language, strict methodological rigor,
assessment of study quality, and sensitivity and sub-
group analyses to investigate the applicability of the
IADPSG criteria in settings other than the HAPO study.
Conclusions
In conclusion, the meta-analyses of studies examining the
WHO and IADPSG criteria demonstrate small increased
risk for adverse pregnancy outcomes, with generally simi-
lar magnitudes of associations for each criteria. For the
WHO criteria, positive associations were consistent
across studies. For the IADPSG criteria, additional stu-
dies will be needed to adequately estimate the magnitude
of associations when applied to non-HAPO settings.
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